Gilead Sciences, Inc. (GILD)
NASDAQ·Healthcare·Drug Manufacturers - General
$128.98
+0.94%
Mkt Cap $168.65B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 10, 2026 | $7.69B | $7.92B | +3.05% | $1.81 | $1.86 | +2.76% | — | — |
| Q4 2025 Oct 30, 2025 | $7.45B | $7.77B | +4.35% | $2.13 | $2.47 | +15.96% | — | — |
| Q3 2025 Aug 7, 2025 | $6.98B | $7.08B | +1.43% | $1.96 | $2.01 | +2.55% | — | — |
| Q2 2025 Apr 24, 2025 | $6.81B | $6.67B | -2.11% | $1.78 | $1.81 | +1.69% | — | — |
| Q1 2025 Feb 11, 2025 | $7.15B | $7.57B | +5.82% | $1.74 | $1.90 | +9.20% | — | — |
| Q4 2024 Nov 6, 2024 | $7.02B | $7.54B | +7.55% | $1.53 | $2.02 | +32.03% | — | — |
| Q3 2024 Aug 8, 2024 | $6.70B | $6.95B | +3.68% | $1.61 | $2.01 | +24.84% | — | — |
| Q2 2024 Apr 25, 2024 | $6.36B | $6.69B | +5.17% | -$1.49 | -$1.32 | +11.41% | — | — |
| Q1 2024 Feb 6, 2024 | $7.10B | $7.12B | +0.20% | $1.76 | $1.72 | -2.27% | — | — |
| Q4 2023 Nov 7, 2023 | $6.42B | $7.05B | +9.86% | $1.91 | $2.29 | +19.90% | — | — |
| Q3 2023 Aug 3, 2023 | $6.46B | $6.60B | +2.19% | $1.60 | $1.34 | -16.25% | — | — |
| Q2 2023 Apr 27, 2023 | $6.46B | $6.35B | -1.60% | $1.63 | $1.37 | -15.95% | — | — |
| Q1 2023 Feb 2, 2023 | $6.64B | $7.39B | +11.36% | $1.50 | $1.67 | +11.33% | — | — |
| Q4 2022 Oct 27, 2022 | $6.13B | $7.04B | +14.87% | $1.44 | $1.90 | +31.94% | — | — |
| Q3 2022 Aug 2, 2022 | $5.86B | $6.26B | +6.80% | $1.51 | $1.58 | +4.64% | — | — |
| Q2 2022 Apr 28, 2022 | $6.29B | $6.59B | +4.85% | $1.77 | $2.12 | +19.77% | — | — |
| Q1 2022 Feb 1, 2022 | $6.61B | $7.24B | +9.51% | $1.53 | $0.69 | -54.90% | — | — |
| Q4 2021 Oct 28, 2021 | $6.15B | $7.42B | +20.58% | $1.75 | $2.65 | +51.43% | — | — |
| Q3 2021 Jul 29, 2021 | $6.22B | $6.22B | +0.00% | $1.76 | $1.87 | +6.25% | — | — |
| Q2 2021 Apr 29, 2021 | $6.68B | $6.42B | -3.90% | $2.06 | $2.08 | +0.97% | — | — |